ad

Top broker picks: Indian Hotels Company & Dr Reddy Laboratories Ltd

Posted by : Avneet Dhamija | Fri Jun 24 2022

Top broker picks:  Indian Hotels Company  &  Dr Reddy Laboratories Ltd

Indian Hotels Company

The Taj Mahal Palace & Tower, in Mumbai, was the first hotel owned by Indian Hotels Company (IHCL), which was founded in 1903. IHCL is a part of the Tata Group, which operates 57 hotels in 40 cities in India. It has 18 hotels in the Maldives, Mauritius, Malaysia, Australia, United Kingdom, United States, Bhutan, Sri Lanka, Africa, and the Middle East in addition to India.

Hotel chains under several brands, including Taj Hotels, Taj Safari, Taj Exotica, The Gateway Hotel, and Ginger, have been developed by IHCL.

Broker’s Call

Broker House

ICICI Securities

Motilal Oswal

IDBI Capital

BUY (INR)

214

215

231

Target (INR)

284

278

278

Upside

+32%

+30%

20%

Time Period

12 Months

12 Months

12 Months

ICICI Securities’ View on IHCL

Revenue Growth & Margin Expansion:

By FY26E, the business anticipates management contracts and new brands (Ginger/Qmin/ama and Chambers) would contribute 25% of total revenue, up from 10% in FY20. With cost savings, a focus on the ideal staff-to-room ratio, and a rationalization of hotel level expenditures, the management is aiming for EBITDA margins of 33% by FY26E.

Funding, capitalization, and simplification:

Through a rights issuance and a QIP, the Company added Rs39.8 billion in equity during the year. The company’s key interests were consolidated with the money raised from these offerings to streamline its holdings and pay off debt. This has enhanced the company’s capital structure and strengthened its balance sheet.

New development bids won in FY22:

During the year, the business won a contract for the development (including management and maintenance) of two hotels, a 4-star hotel and a 3-star hotel, in Kevadia, Gujarat, the location of the Statue of Unity. The winning bidder must form new businesses to serve as incubators for these initiatives in accordance with the bid requirement.

Motilal Oswal’ View on IHCL

Traditional & Innovative Business growth:

The Chambers, the private business club of Taj, has more than 2,200 members as of this writing. It made Rs 850 million in revenue in FY22 and has the potential to reach Rs 1.5 billion by FY26. With a flow through of 75%, “The Chambers” has a larger profit margin.

 

Massive expansion plans

Indian Hotels has a pipeline of 60 Hotels (over 7,500 rooms) with a well-diversified mix of Taj (32%), SeleQtions (9%), Vivanta (19%), and Ginger (40%). Under this robust Hotel pipeline, the share of management contracts is 74%. The remaining 26% is owned by the company. And 92% of the owned hotels belong to the Ginger brand.

 

IDBI Capital’ View

  • IHCL unveiled AHVAAN 2025, which focuses on the company’s strategy for profitable expansion through FY2025/26.

  • With 100 Taj, 75 Vivanta & Seleqtions, 125 Ginger, and +500 Ama stays, the firm will increase its portfolio of hotels to +300. It would aim for an EBITDA margin of 33% and anticipates a 35% EBITDA from new brands and management fees. It aims to have a 50-50 hotel portfolio and concentrates on having no net debt.
  • Company stated by leveraging the Tata ecosystem it has potential to contribute 30% of IHCL’s enterprise revenue in 3 years and synergize with Tata group aviation companies for driving base occupancies, curated trips ,Joint promotions and Air Catering.

 

Dr Reddy Laboratories Ltd

Dr Reddy’s Laboratories Ltd (DRL) is an integrated worldwide pharmaceutical corporation. The primary therapeutic areas on which the firm focuses include dermatology, cancer, diabetology, gastroenterology, and diabetology. Markets all around the world are served by Dr Reddy’s. The USA, India, Russia & CIS nations, and Europe are some of its key markets.

Broker’s Call

Broker House

ICICI Direct

Prabhudas Lilladhar

BUY (INR)

4200

4269

Target (INR)

4960

4900

Upside

+18%

+14%

Time Period

12 Months

12 Months

ICICI Direct’ View

Emerging Markets-

In the next five years, Dr Reddy’s wants to increase sales in China by 2-3 times. The business aims to win Chinese GPO bids. In the present, 17 files are awaiting clearance, and 15 more are anticipated in FY23. With a particular focus on cancer and institutional business, Dr. Reddy’s seeks to grow 4-5 times in Brazil in the next five years.

Productivity Increased-

Operational productivity in the last four years has improved in the following areas – a) API: 35% lower operating expenditure as percentage of sales, b) OSD: 39% lower US$/000’ units and c) sterile: 83% lower US$/unit.

Prabhudas Liladhar’s Views

New growth avenues:

Company is planning to build its Immuno-oncology in NCEs, Biologics & CGT, Nutraceuticals, CDMO, new disease management and digital services which will start contributing meaningfully from 2027. We believe, investments in these avenues will lead to overall 50-100bps increase of expenses. the-counter drugs, and inorganic routes will expand the local formulation industry.

US –robust pipeline:

Dr Reddy’s has robust pipeline of 175 products with 90 filed, out of which 40% are injectables/sterile products. Filings for complex products will continue to focus on +25 products across Drug-device combos, peptides and long-acting Injectables. Contribution from US has come down from 50% in FY16 to 37%. In the near term non US markets will continue to grow faster than US generics.

Note – This channel is for educational and training purpose only & any stock mentioned here should not be taken as a tip/recommendation/advice

Research done by: Ketan Sonalkar, SEBI Rgn No INA000011255

icon

100% Safe & Secure Platform.

Univest encrypts all data and transactions to ensure a completely secure experience for our members.

Copyright

2025 Univest. All rights reserved. | Designed with ❤️ in India
About Univest
About: Univest is a cutting-edge stock market platform designed to help traders and investors maximize their returns with expert-driven advisory services and seamless trading execution. Whether you're a seasoned trader or just starting, Univest simplifies your investment journey with actionable trade recommendations, AI-powered portfolio insights, and a fully integrated brokerage experience. With Univest, you gain access to proven stock market advisory, offering expert trade ideas for stocks, futures, options, and commodities. Our one-click trade execution feature eliminates slippage, ensuring instant execution through our advisory-first brokerage. Smart portfolio management allows you to identify underperforming stocks, optimize your investments, and receive real-time alerts. Additionally, Univest provides seamless investment opportunities beyond stocks, including mutual funds, bonds, fixed deposits, and insurance (coming soon). Join over 40 lakh active investors who trust Univest to make informed and profitable trading decisions. Start investing smarter today! 🚀  
Attention Investors : To ensure a smooth trading experience and prevent unauthorized transactions, investors must update their mobile number and email ID with their stockbroker or depository participant. As per regulatory requirements, investors are required to pay a stipulated amount as an upfront margin for trading in the Cash/FO segment. We encourage all investors to regularly check their securities in the Consolidated Account Statement (CAS) issued by depository to verify their holdings.Always verify alerts and transaction details received directly from the exchange or NSDL before proceeding with any trades. Please do not make payments through unverified email links, WhatsApp, or SMS. Always trade through a registered stockbroker and verify all details before making financial decisions.
 
Disclaimer: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. For more disclaimer /disclosure, visit https://univest.in/stock-broker or Univest App.We collect and use your contact information for legitimate business purposes, including providing updates on our products and services. We do not sell or rent your contact information to third parties. By submitting your details, you authorize us to contact you via Call/SMS, even if you are registered under DND. This authorization remains valid for 12 months.For grievances, please contact us at hello@unibrokers.in .
 
Univest Stock Broking Disclosures
Univest Stock Broking Private Limited - SEBI Reg. No. INZ000317437 (Stock Broker), NSE TM Code: 90392, BSE TM Code: 6866, MCX TM Code: 57290 and ICCL- Self Clearing Member Code: 6866, SEBI Reg. No. IN-DP-779-2024 (Participant), NSDL DP ID: IN304748.
 Risk Disclosures on Derivatives
1. 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
2. On an average, loss makers registered net trading loss close to ₹ 50,000
3. Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
4. Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Attention Investors: As per NSE circular dated July 6, 2022: https://nsearchives.nseindia.com/content/circulars/INSP52900.pdf, BSE circular dated July 6, 2022: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220706-55, MCX circular dated July 11, 2022: https://www.mcxindia.com/docs/default-source/circulars/english/2022/july/circular-418-2022.pdf?sfvrsn=9401991_0, investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. 
Investors are further cautioned to avoid practices like:
a. Sharing 
i) trading credentials – login id and passwords including OTPs.
ii) trading strategies,
iii) position details.
b. Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c. Writing/ selling options or trading in option strategies based on tips, without basic knowledge and understanding of the product and its risks.
d. Dealing in unsolicited tips through platforms like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e. Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.
 Kindly read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets: https://nsearchives.nseindia.com/content/circulars/INSP49434.pdf
Kindly, read the advisory as prescribed by the Exchange with reference to their circular: NSE/ISC/51035 dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: https://www.nseindia.com/resources/exchange-communication-circulars# 
Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from NSDL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (Broker, DP), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Univest Stock Broking Private Limited and offering such services, please send us an email at hello@unibrokers.in
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number. Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL every month.
Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the- indian-securities-market_74794.html. ODR portal for Investors - https://smartodr.in/login.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
General
arrow down